Physician profile
Amando Garza
NPI 1174883177
$548.79
in general payments reported to CMS, 2019-2025
15 companies · $88.58 in 2025
The $88.58 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.21 · 2020: $134 · 2021: $143 · 2022: $29.64 · 2023: $61.15 · 2024: $62.35 · 2025: $88.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $212.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112.22 | 2020-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $88.91 | 2021-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $56.57 | 2020-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $55.89 | 2021 | |
| Lilly USA, LLC | $53.75 | 2020-2023 | Mounjaro |
| Corcept Therapeutics | $35.49 | 2021 | |
| Tactile Systems Technology INC | $31.02 | 2020 | |
| Ironshore Pharmaceuticals INC. | $26.38 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $16.98 | 2019 | |
| Medtronic Minimed, INC. | $16.40 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.70 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.21 | 2022 | |
| Corium, LLC | $14.46 | 2023 | Azstarys |
| Sonex Health, INC. | $9.81 | 2024 | Sx-One Microknife |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amando Garza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.